ESR2 and breast carcinoma: Most previous studies reported estrogen receptors as a prognostic marker for hormone‐related tumors, such as ESR1 in thyroid carcinoma, and ESR1 and ESR2 in ovarian and breast cancer.9, 11, 12, 44